Meeting
2018 ASCO Annual Meeting
Progression-free survival (PFS) and cardiac-toxicity-adjusted-PFS (CTA-PFS) as predictors of overall survival (OS) in locally advanced non-small cell lung cancers (LA-NSCLC) treated with concurrent chemoradiation (CCRT): A secondary analysis of NRG Oncology RTOG 0617.
Authors
Chen Hu
Johns Hopkins University, Baltimore, MD
Chen Hu , Mitchell Machtay , James J. Dignam , Rebecca Paulus , Jeffrey D Bradley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8539)
DOI
10.1200/JCO.2018.36.15_suppl.8539
Abstract #
8539
Poster Bd #
145
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
First Author: Ramesh Rengan
Poster
2011 ASCO Annual Meeting
Concurrent chemoradiotherapy with or without induction chemotherapy for locally advanced head and neck cancer.
First Author: J. J. Caudell
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2023 ASCO Annual Meeting
Thoracic SMARCA4-deficient cancer descriptors and clinicopathologic determinants of survival: Analysis of a pooled database.
First Author: Frankie Lee Powell